Gene and sugar response study with oral semaglutide
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You are male, or female and not pregnant
- Your fasting blood sugar is between 100 and 125 mg/dL based on past lab results
- You are not currently taking medication for diabetes
- You have not had weight loss surgery, gallbladder disease, pancreatitis, or certain digestive issues
- You do not have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
Hear when a new Genetic Predisposition trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.